TriangleVenetoclax (NCT05955261)
Venetoclax trial for Acute Myeloid Leukemia (NCT05955261). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged 29 days through 21 years with newly diagnosed acute myeloid leukemia, myeloid sarcoma or qualifying myelodysplastic syndrome.
The idea: add oral venetoclax to chemotherapy selected by cancer genetics and treatment response. Venetoclax blocks BCL-2, a cell-survival protein. Some patients also receive gilteritinib for FLT3 activation. High-risk patients may proceed to stem-cell transplant; it is not required for everyone. Researchers assess safety and remaining leukemia.
This phase 2 study plans 70 patients. St. Jude’s Hiroto Inaba leads it in Memphis, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.